<DOC>
	<DOCNO>NCT01506440</DOCNO>
	<brief_summary>This pilot clinical trial study cognitive assessment patient cancer undergo chemotherapy . Questionnaires measure cognitive change chemotherapy may help identify side effect chemotherapy .</brief_summary>
	<brief_title>Cognitive Assessments Patients With Cancer Undergoing Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility administer cognitive assessment battery medical oncology clinic . SECONDARY OBJECTIVES : I . To estimate variability various cognitive test assess change cognitive performance base result cognitive assessment obtain prior chemotherapy 6 8 week 12 16 week initiation chemotherapy . II . To explore association cognitive performance Eastern Cooperative Oncology Group ( ECOG ) performance status evaluate patient 's oncology team . III . To assess association cognitive performance occurrence serious adverse event chemotherapy . OUTLINE : Patients complete cognitive assessment , comprise Hopkins Verbal Learning Test-Revised ( HVLT-R ) , Trail Making Test Parts A &amp; B ( TMT-A , TMT-B ) , Digit Symbol Coding Test ( DSC ) , Category Fluency Test ( Animals ) , Montreal Cognitive Assessment ( MoCA ) , Digit Span Test ( DST ) . Patients also complete Beck Depression Inventory . Assessments administer day 1 chemotherapy 6-8 week 12-16 week day 1 chemotherapy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must histologically cytologically confirmed cancer Patients candidate systemic chemotherapy cancer diagnosis Life expectancy must great 6 month Ability understand willingness sign write informed consent document Patients prior systemic chemotherapy lifetime Patients know brain metastasis exclude clinical trial often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event Patients may participate study investigate cognitive function Patients nonEnglish speak ineligible Patients hematologic malignancy ineligible Patients primary central nervous system malignancy ineligible</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>